Cross-protecting
The present invention discloses that Salmonella enterica serogroup C2-3 serovars cross protect against Salmonella enterica serogroup C1 serovars and vice versa. Therefore, the present invention discloses the use of either a Salmonella enterica serogroup C2-3 serovar or a Salmonella enterica serogroup C1 serovar in the manufacture of a vaccine for administration to poultry to protect against a disorder arising from a Salmonella enterica serogroup C2-3 serovar and/or a disorder arising from a Salmonella enterica serogroup C1 serovar.
1. A trivalent Salmonella vaccine comprising a liquid suspension of formalin-killed, iron-restricted Salmonella enterica serogroup C1 Infantis serovar cells, Salmonella enterica serogroup D Enteritidis serovar cells, and Salmonella enterica serogroup B Typhimurium serovar cells, and an aluminium hydroxide adjuvant; wherein said serogroup C1 serovar cells, said serogroup D serovar cells, and said serogroup B serovar cells all had been grown in an iron-restricted medium that comprised an iron chelator; and wherein when administered to a flock of poultry said trivalent Salmonella vaccine provides protection against a disorder arising from a Salmonella enterica serogroup C2-3 infection.
2. The trivalent Salmonella vaccine of claim 1 , that further includes one or more strains of avian rhinotracheitis, infectious bronchitis virus, Newcastle disease virus, and egg drop syndrome virus.